6/30/23, 12:07 AM UPLIFT Pathway Feedback Search Clinical Topics Home Studies UPLIFT UPLIFT Disease Chronic obstructive pulmonary Trial question What is the role of tiotropium in patients with COPD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 25.0% female N = 5993 75.0% male 5993 patients (1519 female, 4473 male) Inclusion criteria: patients with moderate-to-very-severe COPD Key exclusion criteria: a history of asthma, a COPD exacerbation or respiratory infection within 4 weeks before screening, a history of pulmonary resection, use of supplemental oxygen for > 12 hours/day, and the presence of a coexisting illness that could preclude participation in the study Interventions N=2987 tiotropium (80 g of ipratropium, four inhalations, followed 60 minutes later by 400 g of albuterol, four inhalations) N=3006 placebo (matching placebo) Primary outcome Incidence of decline in post-bronchodilator forced expiratory volume in 1 second 42 42 0 mL/year 40 https://web.pathway.md/studies/rectburr9SmEJPNMC 1/2 6/30/23, 12:07 AM UPLIFT Pathway 42.0 mL/year 40 31.5 mL/year 21.0 mL/year 10.5 mL/year No significant difference 0.0 mL/year Tiotropium Placebo No significant difference in the incidence of decline in post-bronchodilator FEV in 1 second (40 mL/year vs. 42 mL/year; MD -2, 95% CI -6 to 2) Secondary outcomes Significant increase in improvement of 4 units in the St. George's Respiratory Questionnaire scores at 4 years (45% vs. 36%; AD 11%, 95% CI 4.47 to 17.53) Significant decrease in median time to first exacerbation (16.7 months vs. 12.5 months; HR 0.86, 95% CI 0.81 to 0.91) No significant difference in the rate of death after 4 years (14.9% vs. 16.5%; HR 0.89, 95% CI 0.79 to 1.02) Safety outcomes No significant difference in adverse events and serious adverse events. Significant difference in fatal events (12.8% vs. 13.7%). Conclusion In patients with moderate-to-very-severe COPD, tiotropium was not superior to placebo with respect to the incidence of decline in post-bronchodilator FEV in 1 second. Reference Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. Open reference URL https://web.pathway.md/studies/rectburr9SmEJPNMC 2/2